Endogenous Incretin Secretagogue Compositions as a Mechanistic Class Versus Pharmacological Incretin Receptor Agonists for Weight Reduction in Overweight Adults: A Real-World Observational Cohort Analysis of a Nutraceutical Composition (Trimsulin) and Comparison with Published Outcomes for Semaglutide and Tirzepatide
Abstract
Abstract Background: Pharmacological glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists such as tirzepatide produce clinically meaningful weight reduction in adults with overweight or obesity. However, gastrointestinal and serious adverse events affect a substantial proportion of treated patients, contributing to discontinuation and limiting long-term adherence. Nutraceutical compositions designed to stimulate endogenous GLP-1 and GIP secretion may offer a tolerability advantage. Objective: To describe weight change and adverse event rates in a real-world cohort of overweight adults using a nutraceutical endogenous incretin secretagogue composition (Trimsulin Weight Loss Program) and to compare these outcomes with publicly available outcome data for semaglutide and tirzepatide. Methods: Observational cohort analysis of 503 overweight adults enrolled in the Trimsulin Weight Loss Program, comprising two nutraceutical products (Control, a powdered drink mix; Thermo, a capsule formulation) taken twice daily before meals, plus a structured dietary protocol and a moderate-exercise recommendation. Body weight, BMI, and participant-reported adverse events were tracked at 12 weeks and 24 weeks. Comparative weight-loss outcomes for semaglutide and tirzepatide were drawn from the on-treatment estimand of the published Truveta-derived real-world cohort analysis by Rodriguez et al.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 18,386 participants or records.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.